These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 18804348

  • 1. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
    Croisier D, Martha B, Piroth L, Chavanet P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
    [Abstract] [Full Text] [Related]

  • 2. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
    Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655
    [Abstract] [Full Text] [Related]

  • 3. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B, Croisier D, Durand D, Hocquet D, Plesiat P, Piroth L, Portier H, Chavanet P.
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO.
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [Abstract] [Full Text] [Related]

  • 6. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF, McElnay JC, Elborn JS, Tunney MM.
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G.
    Pathol Biol (Paris); 2005 Nov; 53(8-9):546-50. PubMed ID: 16023303
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM, Kang SL, Palmer SM, Rybak MJ.
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, Le Conte P, Baron D, Potel G.
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [Abstract] [Full Text] [Related]

  • 14. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML.
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [Abstract] [Full Text] [Related]

  • 19. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.